hotspot -WSS

hotspot

author：focus 2025-09-06 04:14:44 - browse：829

Person wearing a smart watch. -- first opinion coverage from STAT — Adobe

The Apple Watch has secured a new qualification from the Food and Drug Administration that could make the smartwatch an appealing tool for medical device companies hoping to illustrate the benefits of a common heart procedure.

Last week, the Apple Watch’s Atrial Fibrillation History feature became the first digital tool qualified under the Medical Device Development Tools (MDDT) program. Released in 2022, the feature estimates a user’s A-fib burden, or how much time they spend in atrial fibrillation, which is an irregular heart rhythm that can cause shortness of breath and fatigue, and is also linked to an increased risk of stroke.

The qualification means that FDA has determined in advance that sponsors can use the feature as a secondary endpoint in clinical trials without having to do additional work. Specifically, the Apple Watch is qualified for use as a secondary endpoint in clinical trials for cardiac ablation devices, which reduce the electrical signals that cause A-fib by scarring the heart with extreme heat or cold energy. Pulsed field ablation is the latest version of the technology, using a controlled electric field to scar tissue rather than the riskier thermal energy.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Jerome Adams on the need for new antivirals for Covid
Next article： JPM 2024: Biotech’s most prolific dealmaker sees a rosy 2024

explore

WSS

Profiling embryos to choose those with higher IQs is almost a reality

Gene therapy denied for Afghan refugee whose father aided U.S.

Readers discuss the intersection of pregnancy and addiction

Arena BioWorks launches in Cambridge to speed drug discovery

Arena BioWorks launches in Cambridge to speed drug discovery

Medical device trials still don't enroll enough women, study finds

leisure time

hotspot

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

Wikipedia

In Memoriam: Notable people who died in 2023

New report analyzes digital physical therapy solutions' effectiveness

Psychedelics group wrestles with new pharma identity

STAT Virtual Event: JPM Recap, Live!

23andMe had bad news about my health. I wish a person had delivered it

Medical device trials still don't enroll enough women, study finds

Dobbs anniversary: the lost opportunity of abortion as health care

Rune Labs, whose app tracks Parkinson's symptoms, raises $12M

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

A preacher's new calling: Diversifying neuroscience research

knowledge

Cigna wins case to block Amy Bricker's move to CVS

Hospital chaplains balance Covid safety with patients’ spiritual needs

'Essentially witchcraft:' A former naturopath takes on the field

A preacher's new calling: Diversifying neuroscience research

Curing rare childhood diseases will falter unless Congress steps up

A preacher's new calling: Diversifying neuroscience research

knowledge

explore

explore

hotspot